59
Views
2
CrossRef citations to date
0
Altmetric
Review

Medical therapy of epilepsy

, MD
Pages 955-964 | Published online: 16 Aug 2007

Bibliography

  • HAUSER WA, ANNEGERS JF, ROCCA WA: Descriptive epidemiology of epilepsy: contributions of population-based studies from Rochester, Minnesota. Mayo. Clin. Proc. (1996) 71(6):576-586.
  • HAUSER WA, HESDORFFER DC: Epilepsy: Frequency, Causes and Consequences. (Ed.), Demos Press, New York, (1991):21-28.
  • ANNEGERS JF: The Epidemiology of Epilepsy. In The Treatment of Epilepsy: Principles and Practice. E W (Ed.), Lippincott Williams and Wilkins, Philadelphia, PA (2001):131-138.
  • DAM M: Goals of therapy. In: Epilepsy: A Comprehensive Textbook. Jr EJ et al. (Eds), Lippincott-Raven, Philadelphia, Pa (1997):1103-1105.
  • KWAN P, BRODIE MJ: Early identification of refractory epilepsy. N. Engl. J. Med. (2000) 342(5):314-319.
  • MARSON AG, KADIR ZA, CHADWICK DW: New antiepileptic drugs: a systematic review of their efficacy and tolerability. BMJ (1996) 313(7066):1169-1174.
  • GAMBLE CL, WILLIAMSON PR, MARSON AG: Lamotrigine versus carbamazepine monotherapy for epilepsy. Cochrane Database Syst. Rev. (2006) (1):CD001031.
  • PELLOCK JM, BRODIE MJ: Felbamate: 1997 update. Epilepsia (1997) 38(12):1261-1264.
  • WHITE HS: Comparative anticonvulsant and mechanistic profile of the established and newer antiepileptic drugs. Epilepsia (1999) 40(Suppl. 5):S2-S10.
  • GLUE P, BANFIELD CR, PERHACH JL et al.: Pharmacokinetic interactions with felbamate. Clin. Pharmacokinet. (1997) 33(3):214-224.
  • PELLOCK JM: Felbamate. Epilepsia (1999) 40 (Suppl. 5):S57-S62.
  • GEE NS, BROWN JP, DISSANAYAKE VU et al.: The novel anticonvulsant drug, gabapentin (Neurontin), binds to the α2δ subunit of a calcium channel. J. Biol. Chem. (1996) 271(10):5768-5776.
  • CHADWICK D, LEIDERMAN DB, SAUERMANN W, ALEXANDER J, GAROFALO E: Gabapentin in generalized seizures. Epilepsy Res. (1996) 25(3):191-197.
  • SHORVON S, STEFAN H: Overview of the safety of newer antiepileptic drugs. Epilepsia (1997) 38 (Suppl. 1):S45-S51.
  • GIDAL BE, DECERCE J, BOCKBRADER HN et al.: Gabapentin bioavailability: effect of dose and frequency of administration in adult patients with epilepsy. Epilepsy Res. (1998) 31(2):91-99.
  • BRODIE MJ: Lamotrigine – an update. Can. J. Neurol. Sci. (1996) 23(4):S6-S9.
  • FITTON A, GOA KL: Lamotrigine. An update of its pharmacology and therapeutic use in epilepsy. Drugs (1995) 50(4):691-713.
  • BRODIE MJ, RICHENS A, YUEN AW: Double-blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. UK Lamotrigine/Carbamazepine Monotherapy Trial Group. Lancet (1995) 345(8948):476-479.
  • BITON V, SACKELLARES JC, VUONG A et al.: Double-blind, placebo-controlled study of lamotrigine in primary generalized tonic-clonic seizures. Neurology (2005) 65(11):1737-1743.
  • GUERRINI R, DRAVET C, GENTON P et al.: Lamotrigine and seizure aggravation in severe myoclonic epilepsy. Epilepsia (1998) 39(5):508-512.
  • BENBADIS SR: Practical management issues for idiopathic generalized epilepsies. Epilepsia (2005) 46 (Suppl. 9):125-132.
  • SIDHU J, JOB S, SINGH S, PHILIPSON R: The pharmacokinetic and pharmacodynamic consequences of the co-administration of lamotrigine and a combined oral contraceptive in healthy female subjects. Br. J. Clin. Pharmacol. (2006) 61(2):191-199.
  • PERUCCA E: A pharmacological and clinical review on topiramate, a new antiepileptic drug. Pharmacol. Res. (1997) 35(4):241-256.
  • SOUSA PDA S, ARAUJO FILHO GM, GARZON E, SAKAMOTO AC, YACUBIAN EM: Topiramate for the treatment of juvenile myoclonic epilepsy. Arq. Neuropsiquiatr. (2005) 63(3B):733-737.
  • LANGTRY HD, GILLIS JC, DAVIS R: Topiramate. A review of its pharmacodynamic and pharmacokinetic properties and clinical efficacy in the management of epilepsy. Drugs (1997) 54(5):752-773.
  • DICHTER MA, BRODIE MJ: New antiepileptic drugs. N. Engl. J. Med. (1996) 334(24):1583-1590.
  • ECKARDT KM, STEINHOFF BJ: Non-convulsive status epilepticus in two patients receiving tiagabine treatment. Epilepsia (1998) 39(6):671-674.
  • ETTINGER AB, BERNAL OG, ANDRIOLA MR et al.: Two cases of non-convulsive status epilepticus in association with tiagabine therapy. (0013-9580 (Print)).
  • KLITGAARD H, MATAGNE A, GOBERT J, WULFERT E: Evidence for a unique profile of levetiracetam in rodent models of seizures and epilepsy. Eur. J. Pharmacol. (1998) 353(2-3):191-206.
  • LAMBENG N, GILLARD M, VERTONGEN P, FUKS B, CHATELAIN P: Characterization of [(3)H]ucb 30889 binding to synaptic vesicle protein 2A in the rat spinal cord. Eur. J. Pharmacol. (2005) 520(1-3):70-76.
  • CEREGHINO JJ, BITON V, ABOU-KHALIL B et al.: Levetiracetam for partial seizures: results of a double-blind, randomized clinical trial. Neurology (2000) 55(2):236-242.
  • ABOU-KHALIL B, LAZENBY B: Long-term experience with levetiracetam. Epileptic Disord. (2003) 5(Suppl. 1):S33-S37.
  • KALIS MM, HUFF NA: Oxcarbazepine, an antiepileptic agent. Clin. Ther. (2001) 23(5):680-700; discussion 645.
  • SCHMIDT D, ELGER CE: What is the evidence that oxcarbazepine and carbamazepine are distinctly different antiepileptic drugs? Epilepsy Behav. (2004) 5(5):627-635.
  • FATTORE C, CIPOLLA G, GATTI G et al.: Induction of ethinylestradiol and levonorgestrel metabolism by oxcarbazepine in healthy women. Epilepsia (1999) 40(6):783-787.
  • GELISSE P, GENTON P, KUATE C, PESENTI A, BALDY-MOULINIER M, CRESPEL A: Worsening of seizures by oxcarbazepine in juvenile idiopathic generalized epilepsies. (0013-9580 (Print)).
  • ASCONAPE JJ: Some common issues in the use of antiepileptic drugs. Semin. Neurol. (2002) 22(1):27-39.
  • PETERS DH, SORKIN EM: Zonisamide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in epilepsy. Drugs (1993) 45(5):760-787.
  • KOTHARE SV, VALENCIA I, KHURANA DS et al.: Efficacy and tolerability of zonisamide in juvenile myoclonic epilepsy. Epileptic Disord (2004) 6(4):267-270.
  • ARROYO S, ANHUT H, KUGLER AR et al.: Pregabalin add-on treatment: a randomized, double-blind, placebo-controlled, dose-response study in adults with partial seizures. Epilepsia (2004) 45(1):20-27.
  • FRENCH JA, KUGLER AR, ROBBINS JL, KNAPP LE, GAROFALO EA: Dose-response trial of pregabalin adjunctive therapy in patients with partial seizures. Neurology (2003) 60(10):1631-1637.
  • BEYDOUN A, UTHMAN BM, KUGLER AR et al.: Safety and efficacy of two pregabalin regimens for add-on treatment of partial epilepsy. Neurology (2005) 64(3):475-480.
  • HAMANDI K, SANDER JW: Pregabalin: a new antiepileptic drug for refractory epilepsy. Seizure (2006) 15(2):73-78.
  • BRODIE MJ: Pregabalin as adjunctive therapy for partial seizures. Epilepsia (2004) 45 (Suppl. 6):19-27.
  • MARSON AG, AL-KHARUSI AM, ALWAIDH M et al.: The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial. (1474-547X (Electronic))
  • MARSON AG, AL-KHARUSI AM, ALWAIDH M et al.: The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalised and unclassifiable epilepsy: an unblinded randomised controlled trial. (1474-547X (Electronic))
  • BEGHI E, ANNEGERS JF: Pregnancy registries in epilepsy. Epilepsia (2001) 42(11):1422-1425.
  • SABERS A, DAM M, A-ROGVI-HANSEN B et al.: Epilepsy and pregnancy: lamotrigine as main drug used. (0001-6314 (Print))
  • TEN BERG K, SAMREN EB, SAMREN EB, VAN OPPEN AC, ENGELSMAN M: Levetiracetam use and pregnancy outcome Epilepsy and pregnancy: lamotrigine as main drug used influence of major antiepileptic drugs on attention, reaction time, and speed of information processing: results from a randomized, double-blind, placebo-controlled withdrawal study of seizure-free epilepsy patients receiving monotherapy Side Effect Profiles and Behavioral Consequences of Antiepileptic Medications New anticonvulsants--new adverse effects. (0890-6238 (Print)).
  • LB H, DF W, EJ B et al.: Increased risk for non-syndromic cleft palate among infants exposed to lamotrigine during pregnancy (abstract). Birth Defects Research Part A: Clinical and Molecular Teratology (2006).
  • LEE S, SZIKLAS V, ANDERMANN F et al.: The effects of adjunctive topiramate on cognitive function in patients with epilepsy. Epilepsia (2003) 44(3):339-347.
  • PACK AM, MORRELL MJ, MARCUS R et al.: Bone mass and turnover in women with epilepsy on antiepileptic drug monotherapy. Ann. Neurol. (2005) 57(2):252-257.
  • STEPHEN LJ, MCLELLAN AR, HARRISON JH et al.: Bone density and antiepileptic drugs: a case-controlled study. Seizure (1999) 8(6):339-342.

Patents

  • CARTER-WALLACE, INC. (NEW YORK, NY): US4868327 (1987).
  • MEDPOINTE PHARM HLC (SOMERSET, NJ): US4978680 (1993).
  • WARNER-LAMBERT COMPANY (MORRIS PLAINS, NJ): US4894476 (1988).
  • THE WELLCOME FOUNDATION LIMITED (MIDDLESEX, GB3): US5861179 (1995).
  • MCNEIL LAB., INC. (FORT WASHINGTON, PA): US4513006 (1983).
  • MCNEIL LAB., INC. (FORT WASHINGTON, PA): US5384327 (1983).
  • NOVO NORDISK A/S. (BAGSVAERD, DK): US5010090 (1988).
  • U C B SOCIETE ANONYME (BRUSSELS, BE): US4696943 (1985).
  • CIBA GEIGY CORPORATION (ARDSLEY, NY): US4559174 (1983).
  • DAINIPPON PHARMACEUTICAL CO., LTD. (OSAKA, JP): US4172896 (1978).
  • WARNER-LAMBERT COMPANY (MORRIS PLAINS, NJ): US6197819 (1995).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.